Clinical Presentation & Protocol
Patient Usually Complains Of
Patient presents with clinical and biochemical evidence of mixed hepatocellular and cholestatic liver injury. Onset of symptoms [insert duration] following initiation of [insert offending agent]. Symptoms include [jaundice/pruritus/fatigue/RUQ discomfort]. R-ratio calculated at [insert value], consistent with mixed pattern. No history of chronic viral hepatitis, alcohol abuse, or autoimmune liver disease.
Clinical Examination Findings
General: Patient appears [non-toxic/jaundiced/ill]. HEENT: Scleral icterus present/absent. Abdomen: Soft, non-distended, mild tenderness to palpation in RUQ, no hepatosplenomegaly or ascites noted. Skin: No stigmata of chronic liver disease (palmar erythema, spider angiomata). Neurological: Alert and oriented x3, no asterixis or signs of hepatic encephalopathy.
Treatment Protocol
1. Immediate discontinuation of suspected hepatotoxic agent [insert agent]. 2. Supportive care with adequate hydration and nutritional support. 3. Monitor LFTs (ALT, AST, ALP, Bilirubin, INR) every [insert frequency]. 4. Consider N-acetylcysteine if acetaminophen toxicity is suspected. 5. Avoid all hepatotoxic medications, including NSAIDs and alcohol. 6. Consult Hepatology if LFTs worsen or signs of liver failure develop.